Search

Displaying results 781 - 790 of 4591 in total
  1. Drug

    Gadobutrol

    go.drugbank.com/drugs/DB06703
    ApprovedInvestigational

    Gadobutrol is a second-generation extracellular non-ionic macrocyclic GBCA (gadolinium-based contrast agent) used in magnetic resonance imaging (MRI) in adults and children older than 2 years of age.

  2. Drug

    Cellspan Esophageal Implant

    go.drugbank.com/drugs/DB18688
    Experimental

    The Cellspan Esophageal ImplantTM (CEI) composes of autologous adipose-derived mesenchymal stromal cells (Ad-MSC) seeded onto a polyurethane tubular mesh cell delivery device.

  3. Drug

    Patent Blue

    go.drugbank.com/drugs/DB13967
    ApprovedInvestigational

    Patent blue was developed by Guerbet and approved by Health Canada on December 31, 1979.[L1113] The isomer isosulphan is used in the United States for the same indications than patent blue.[A32574]

  4. Drug

    Sertaconazole

    go.drugbank.com/drugs/DB01153
    Approved

    Sertaconazole nitrate is an antifungal medication of the imidazole class. It is available in topical formulations for the treatment of skin infections such as athlete's foot.

  5. Drug

    Indalpine

    go.drugbank.com/drugs/DB08953
    ApprovedWithdrawn

    However, after the emergence of widespread concern regarding adverse effects caused by SSRIs, and reported hematological effects caused by Indalpine, it was abruptly withdrawn from the US market. … It was initially marketed by Pharmuka.

  6. Drug

    Levobetaxolol

    go.drugbank.com/drugs/DB09351
    Approved

    It was marketed as a 0.5% ophthalmic solution of levobetaxolol hydrochloride under the trade name Betaxon but has been discontinued.

  7. Drug

    Fosnetupitant

    go.drugbank.com/drugs/DB14019
    ApprovedInvestigational

    In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alte...

  8. Drug

    Tetrachlorodecaoxide

    go.drugbank.com/drugs/DB05389
    Approved

    WF10 is a chlorite-based, immunomodulating drug is developed by Nuvo Research Inc. Certain preclinical evidence and clinical pilot data suggest that WF10 may be effective in treating certain cancers. … The Corporation believes the research to-date demonstrates that WF10 acts on macrophages (a type of white blood cell) by modulating the balance between inflammation and phagocytosis, a state in which the

  9. Drug

    Desflurane

    go.drugbank.com/drugs/DB01189
    ApprovedInvestigational

    Desflurane, or I-653, a a volatile anesthetic that is more rapidly cleared and less metabolized than previous inhaled anesthetics such as methoxyflurane, sevoflurane, enflurane, or isoflurane. . It was developed in the late 1980s out of ...

  10. Drug

    Clesrovimab

    go.drugbank.com/drugs/DB18877
    Approved

    [A273953,A273978] Clesrovimab-cfor was approved by the US FDA in June 2025 for use in infants prior to or during their first RSV season.[L53228,L53233]